Abstract: The present invention relates to a whey-derived polar lipid-concentrated fraction composition, being a single-phase composition derived from a whey protein concentrate, wherein the composition is derived from a fraction obtained by treating the whey protein concentrate with a water-containing spirit, a total lipid content is 90 percent by weight (wt %) or more with respect to a dry weight of the composition, and a phospholipid content is 35 wt % or more with respect to the total lipid weight. According to the present invention, a whey-derived polar lipid-concentrated fraction composition in a stable form that maximizes emulsification and physiological functionality may be prepared.

Abstract: A novel sphingolipid is disclosed. The novel sphingolipid is in liquid form at room temperature due to a low melting point, and blends easily with a variety of vegetable and/or animal oils. A dermatologic composition for external application containing the novel sphingolipid is also disclosed. The composition is useful in providing anti-inflammatory protection, improving moisturization, protecting the skin from ultraviolet (UV) light, or enhancing skin barriers.

Abstract: A topical skin composition containing a sphingolipid having a branched chain fatty acid as an active ingredient and its uses are disclosed. The topical composition is useful in preventing adsorption of fine dust, improving a skin barrier function, and exhibiting an excellent skin moisture effect. A preparation method for the topical composition is also disclosed.

Abstract: The present disclosure relates to a novel yeast mutant strain for producing a ceramide precursor, and a method for preparing the same, and more specifically, to a Pichia ciferrii mutant strain genetically engineered to overexpress sphingolipid metabolites prepared through the reconstruction of metabolic pathways for ceramide production in Pichia ciferrii, or a method for preparing the mutant strain.